SS-31 Peptide SubQ Dosage: What Research Actually Shows

There is no established subcutaneous (subQ) dosage of SS-31 for human use. SS-31, also known as elamipretide, is an investigational mitochondrial peptide that is not FDA-approved, so every human dose on record comes from controlled clinical trials rather than consumer protocols. Published trial parameters should be read as research data, not as a personal dosing plan.

What Is SS-31 (Elamipretide)?

SS-31 is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It is designed to concentrate inside mitochondria and bind to cardiolipin, a phospholipid that sits on the inner mitochondrial membrane.

Laboratory work suggests the peptide may help stabilize mitochondrial structure and reduce oxidative stress during energy production. That mechanism is why researchers study it in conditions tied to mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.

SS-31 is not a hormone, not a SARM, and not a dietary supplement. It has no approved human indication in the United States, which means no manufacturer can legally sell it for human consumption.

Why There Is No Official SS-31 SubQ Dosage

Drug dosages become standard only after regulators review safety and efficacy data. SS-31 has not cleared that process, so no subQ dose is approved or universally accepted.

• Investigational status: Elamipretide remains an investigational new drug, and human exposure happens inside trial protocols.
• Indication matters: A dose studied for Barth syndrome is not automatically appropriate for another condition.
• Formulation matters: Concentration, injection volume, and frequency vary between studies.
• Research-grade products are not drugs: Vials labeled "for research use only" are not manufactured to pharmaceutical sterility standards.

Anyone comparing ss-31 peptide dosage recommendations online will find wide disagreement, because there is no regulatory benchmark to anchor the numbers. Most of those figures were copied from animal studies or from early-phase safety work that was never designed to define a treatment dose.

SS-31 Dosing Reported in Published Research

The table below summarizes parameters reported in public trial summaries and preclinical publications. These figures describe study protocols, not recommendations for individual use.

Program or study type	Route	Reported dose	Frequency
TAZPOWER (Barth syndrome)	Subcutaneous	40 mg	Once daily
MMPOWER-3 (primary mitochondrial myopathy)	Subcutaneous	40 mg	Once daily
ReCLAIM / ReCLAIM-2 (dry AMD)	Subcutaneous	40 mg	Once daily
Early phase 1 pharmacokinetics	Intravenous infusion	0.01–0.25 mg/kg/hr range	Single ascending doses
Preclinical rodent studies	Subcutaneous or intraperitoneal	1–5 mg/kg	Daily, for limited study periods

The most consistent human number is 40 mg given subcutaneously once per day. That figure appears across multiple phase 2 and phase 3 programs, which makes it the most frequently cited ss-31 peptide injection dosage in the published literature.

Why 40 mg Appears So Often

Elamipretide has a short plasma half-life, so once-daily subcutaneous delivery was chosen to maintain reasonable tissue exposure without continuous infusion. Trial sponsors also kept the dose fixed to make safety signals easier to interpret across sites.

A fixed dose does not mean 40 mg is optimal, safe for everyone, or appropriate for any other purpose. It simply means 40 mg is what most human studies used.

What a SubQ Injection Actually Involves

Subcutaneous administration delivers a substance into the fatty layer just beneath the skin, usually in the abdomen, thigh, or upper arm. Absorption is slower and more gradual than intravenous delivery.

Standard practice in clinical settings includes sterile technique, single-use needles, rotating injection sites, and observing the area afterward. Injection site reactions such as redness, bruising, or tenderness are the most commonly reported side effects in elamipretide trials, along with occasional headache, nausea, or dizziness.

Self-injecting a research chemical outside a clinical setting carries risks that a trial protocol is built to manage, including contamination, incorrect concentration, and delayed recognition of an adverse reaction.

Community Claims vs. What Research Shows

Online discussions often present numbers that do not appear in any published human trial. The comparison below separates common claims from the available evidence.

Common community claim	What the research record shows
An ss-31 peptide dosage 10mg per day is standard	No major published human trial uses 10 mg once daily as its primary subQ regimen; 40 mg daily is the most frequently reported
The peptide builds muscle or boosts athletic performance	No controlled human trial has measured muscle growth, strength, or endurance outcomes in athletes
Higher doses produce better results	A human dose-response relationship has not been established, and higher exposure has not been shown to improve outcomes
Any source is fine as long as the label matches	Identity, purity, and sterility vary widely in research-grade supply chains, and independent testing is uncommon

People searching for ss-31 peptide bodybuilding dosage are usually chasing recovery, endurance, or fat-loss claims that have never been tested in a controlled athletic population. Fitness forums tend to recycle rodent and veterinary figures without noting the species gap between mice and humans.

Researchers studying ss-31 peptide benefits focus on mitochondrial energy output, cardiac function, and vision outcomes, not on physique metrics. That distinction matters when evaluating marketing language.

Safety, Legal Status, and Sourcing

SS-31 is not approved by the FDA for any human condition, and it cannot legally be sold as a dietary supplement. Products marketed to consumers are typically labeled for laboratory research only.

That label is not a formality. Research-grade peptides may contain impurities, bacterial endotoxins, or incorrect concentrations, and no regulatory body verifies what is inside the vial before shipment.

Athletes should check current anti-doping rules, because many peptides fall under prohibited categories even when they are not named individually. Anyone with a genuine medical interest in elamipretide should speak with a healthcare professional and look for an approved clinical trial rather than self-dosing with research material.

Key Takeaways

• No SS-31 subQ dosage is FDA-approved for human use.
• Clinical trials have most often reported 40 mg subcutaneously once daily.
• Community numbers such as 10 mg per day are not supported by major human trial data.
• Published benefits center on mitochondrial function, not muscle growth or athletic performance.
• Sterility, purity, and legal status are real concerns with non-pharmaceutical sources.

COMMON QUESTIONS

Frequently Asked Questions

What SS-31 subQ dosage is used in human studies?

The most frequently reported human protocol is 40 mg given subcutaneously once daily, used in trials for Barth syndrome, primary mitochondrial myopathy, and dry age-related macular degeneration. That dose is a study parameter, not an approved or recommended regimen. No SS-31 dose has been cleared by the FDA for human use.

Can I inject SS-31 peptide at home?

SS-31 is an investigational drug, so legal human use occurs inside clinical trials or under physician supervision. Consumer vials sold online are labeled for research use only and are not manufactured to pharmaceutical sterility standards. Self-injecting an unverified peptide risks contamination, dosing errors, and unrecognized adverse reactions.

Is SS-31 the same as other mitochondrial peptides?

No. SS-31, or elamipretide, is a specific synthetic tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. It is distinct from other research peptides such as MOTS-c or humanin, which have different structures, mechanisms, and study protocols. Dosing data from one peptide does not transfer to another.